Smoldering Systemic Mastocytosis — Trials

Smoldering Systemic Mastocytosis — Trials · CancerIndex

Clinical trials

Registered studies

3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–3 of 3 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04910685	(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis	recruiting	Phase 2 / Phase 3	534	Blueprint Medicines CorporationINDUSTRY	23	Sep 23, 2026	clinicaltrials
NCT05186753	(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis	active not recruiting	Phase 2	237	Cogent Biosciences, Inc.INDUSTRY	15	May 22, 2026	clinicaltrials
NCT02380222	Patient-Reported Outcome Questionnaire for Systemic Mastocytosis	completed	—	5	Adelphi Values LLCINDUSTRY	1	Jan 10, 2017	clinicaltrials

Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials